ArticlePloS one2017
Decreased prevalence of cancer in patients with multiple sclerosis: A case-control study.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Gastrointestinal symptoms and disorders in multiple sclerosis: a systematic review and meta-analysis.Journal of neurology · 2026Pooled it
- A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications.Journal of neurology · 2021Pooled it
- Updated Review for Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection.Journal of lower genital tract disease · 2025Review
- Comparison of early visual outcomes after SMILE using VISUMAX 800 and VISUMAX 500 for myopia: a retrospective matched case-control study.Scientific reports · 2024Article
- Trajectories network analysis of chronic diseases among middle-aged and older adults: evidence from the China Health and Retirement Longitudinal Study (CHARLS).BMC public health · 2024Article
- Is cancer risk reduced in multiple sclerosis? Results from a tertiary referral center.Turkish journal of medical sciences · 2023Article
- Association between multiple sclerosis and prostate cancer risk: A systematic review and meta‑analysis.Oncology letters · 2023Article
- Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies.Frontiers in neurology · 2023Review
- Occurrence of malignant diseases in patients with multiple sclerosis: population-based MS Registry data.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Article
- Cancer risk for multiple sclerosis patients treated with azathioprine and disease-modifying therapies: an Italian observational study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Observational
- Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.Scientific reports · 2021Article
- Multiple sclerosis, human herpesvirus 4 and thyroid collision tumor: A case report.Experimental and therapeutic medicine · 2020Article
- Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies.Frontiers in immunology · 2019Review
- Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort.Frontiers in neurology · 2019Article
- Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs.CNS drugs · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStudies of cancer prevalence have produced conflicting results concerning the relative risk of overall and specific sub-types of cancer in patients with multiple sclerosis (MS). Contemporary controls and information on tobacco use and alcohol consumption are generally missing from previous studies.
objectivesTo evaluate lifetime cancer prevalence in a large cohort of MS patients relative to appropriate controls.
methodsWe conducted a case-control study, using a postal survey of a cohort of MS patients. Of the 1574 questionnaires sent, 1107 could be used for statistical analysis. Data from 1568 controls were prospectively collected using the same self-administered survey among consecutive out-patients in a single neurology department. Propensity scores matched on age, gender, and history of smoking and alcohol consumption were calculated.
resultsAmong the MS patients, 7.32% had ever presented with a cancer, whereas 12,63% of the controls had, leading to a bootstrap matched odds ratio (OR) of 0.63; 95% CI 0.57-0.70. Although only exploratory, the use of DMT (immunomodulators or immunosupressants) did not appear to increase this risk (p = 0.42). The disease course also did not affect cancer prevalence.
conclusionMS was associated with a reduced overall cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.